GBG
Government
Bioscience
Grants

Updated Monthly

July 8, 2026

Prepared for:

BIOUTAH

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:

G2G Consulting

Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com
@G2Gconsulting

GBG Report

Updated Monthly

July 8, 2026

https://www.g2gconsulting.com/gbg-reporting-service/

TABLE OF CONTENTS

New Opportunities

Recurring Opportunities

GBG Report

Updated Monthly

July 8, 2026

https://www.g2gconsulting.com/gbg-reporting-service/

July 16, 2026 – Join us for G2G's Monthly Non-Dilutive Funding: GBG Reporting Service Webinar at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you're an affiliate of Biocom, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, VaBio, or BioWV – your membership gets you access to the private consultation meeting.

Major Policy Changes – The comment period for a proposed rule that will significantly change federal grants policy, closes on July 13.

MHSRS 2026 registration is open! This is a great opportunity for your company to make inroads with military medical stakeholders. If you are interested in working with G2G to maximize participation at this 4-day meeting from August 3-6 in Florida, please reach out by July 13!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (1)		
1.	Renewal of the Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NIA/OAR) RFA-AG-27-007	This NOFO intends to build upon NIA's substantial investments to foster the development of clinician-scientists across specialties and disciplines. The specific goals of this initiative are to convey scientific and research knowledge on aging research; foster networking and collaboration between clinician-scientist leaders in aging research and clinician-investigators across specialties and disciplines who wish to focus on aging research; provide mentoring and career development support for emerging clinician-scientists committed to pursuing aging research in their clinical specialty or discipline; and advance interdisciplinary research projects in aging. https://www.grants.gov/search-results-detail/359651	Up To $1.5 million, for up to 5 years	Proposal: 9/29/26
		ANTIBIOTIC RESISTANCE (1)		
2.	Resistance Networks (Wellcome/Leap)	The goal of Resistance Networks is to build an epidemiological model that can predict whether a plasmid carrying antibiotic resistance genes (pARG) has epidemic-like potential — an R_0 greater than 1 — to spread within and between human bacterial networks during and after antibiotic use. https://wellcomeleap.org/programs/resistance-networks/	Total funding of $50 million	Abstract: 7/22/26 Proposal: 9/4/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (5)		
3.	Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01/U24/U54 Clinical Trial Not Allowed/UG3/UH3 Clinical Trial Optional) (NIH Common Fund) RFA-RM-27-011 (U01) RFA-RM-27-012 (UG3/UH3) RFA-RM-27-013 (UG3/UH3) RFA-RM-27-014 (U54) RFA-RM-27-015 (U24)	The overarching goal of these NOFOs is to establish the PRIMED-AI Program to support development of innovative, reliable, cost-effective, and sustainable multimodal AI-based clinical decision support (CDS) tools. PRIMED-AI CDS tools are based on the integration of clinical imaging with other types of multimodal health data to enhance care for patients with a wide range of health conditions. Components include: Development and Testing of a Multi-use Frameworks Playbook; Data-to-Model Academic-Industrial Partnerships (D2M-AIP); Model-to-Clinic (M2C); a Validation Center; and a Logistics Center. https://www.grants.gov/search-results-detail/359271 (U01) https://www.grants.gov/search-results-detail/359270 (UG3/UH3) https://www.grants.gov/search-results-detail/359666 (UG3/UH3) https://www.grants.gov/search-results-detail/359269 (U54) https://www.grants.gov/search-results-detail/359268 (U24)	Up to $300,000 per year, for up to 2 years (U01) Up to $450,000 per year (UG3) Up to $1 million per year (UH3) Up to $14.8 million, for up to 5 years (U54) Up to $10.575 million, for up to 5 years (U24)	Proposal: 10/2/26
		ASTHMA AND ALLERGIC DISEASES (2)		
4.	Forecast: Childhood Asthma in Urban Settings Clinical Research Network (NIH/NIAID) RFA-AI-28-007	The CAUSE network will support multi-site clinical studies and trials on the prevention and treatment of asthma in economically disadvantaged pediatric populations where disease burden is high. The objectives of the CAUSE network are to develop and test innovative hypotheses and strategies for asthma prevention; identify/test new treatment targets; and continue to explore the risk relationship between upper and lower airway. Using systems biology approaches, CAUSE will continue to identify disease endotypes that may be suitable targets for existing and novel therapeutic modalities. https://www.grants.gov/search-results-detail/362950	Total funding of $8.38 million	Estimated post date: 1/8/27 Estimated proposal date: 5/28/27
5.	Forecast: Asthma and Allergic Diseases Cooperative Research Centers (NIH/NIAID) RFA-AI-28-009	The AADCRC program serves as the cornerstone of NIAID's efforts to promote clinical and basic research in diseases including asthma, upper airway allergic/inflammatory diseases, food and drug allergies, atopic dermatitis, and other allergic diseases. The overarching goals of this program are to investigate mechanisms underlying the onset, progression, treatment modalities, and mechanisms of treatment response for the diseases of interest. Goals of the program may include exploring disease mechanisms and/or treatment modalities in small clinical trials/observational studies or immune pathway-focused projects using primarily human materials. https://www.grants.gov/search-results-detail/362953	Total funding of $7.674 million	Estimated post date: 1/5/27 Estimated proposal date: 5/21/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH (5)		
6.	Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed) (NIH) PAR-27-021	This NOFO aims to build new research capacity and develop a sustainable research program by supporting the purchase of a single commercially available biomedical research instrument currently unavailable in the institution. Instruments funded through this program must be shared among the users to create new research opportunities, enable reproducible data generation, encourage collaborative research and training, and strengthen long-term research capabilities. https://www.grants.gov/search-results-detail/360882	Up to $400,000	Multiple deadlines; NOFO open through 7/1/28
7.	Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) (NIH) PAR-27-022	This NOFO announces the restructured SIG Program that consolidates three existing shared-use instrumentation programs, i.e., the Shared Instrumentation Grant program, the High-End Instrumentation Grant program, and the Basic Instrumentation Grant program. The NOFO invites applications from groups of NIH-supported investigators to purchase or upgrade a single state-of-the-art commercially available instrument or an integrated instrumentation system. The instruments purchased through the SIG Program are required to be optimally shared among the users to ensure efficient and cost-effective research operations, enable rigorous and reproducible measurements, and encourage collaborative research and benefit broad research communities at large. https://www.grants.gov/search-results-detail/360532	Up to $5 million	Multiple deadlines; NOFO open through 7/1/28
8.	Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed) (NIH/NIGMS) PAR-27-024	This NOFO encourages applications for NIGMS Biomedical Technology Optimization and Dissemination (BTOD) Centers to support late-stage technology optimization and sustainable dissemination of the technologies to the wider biomedical research community. A BTOD Center should be at the leading edge of its field with respect to both technology optimization and engagement with relevant research communities. BTOD projects must address biomedical research areas within the NIGMS mission. https://www.grants.gov/search-results-detail/360446	Up to $850,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 1/29/29
9.	Forecast: National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional) (NIH/NCBIB) PAR-27-105	This NOFO will encourage grant applications for National Centers for Biomedical Imaging and Bioengineering (NCBIB). NCBIB are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. NCBIB also make their technologies available to other investigators, train members of the research community in the use of the technologies and disseminate the technologies broadly. https://www.grants.gov/search-results-detail/362722	TBD	Estimated post date: 9/26/26 Estimated proposal date: 1/25/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
10.	Pre-Announcement: "Multi-Topic Request for Proposals: Military Medical Prototype Advancement" (MTEC)	This RPP will solicit a broad range of medical prototype technological and knowledge solutions related to the Focus Areas of Interest. Areas include: Prophylactic Solutions to Prevent Battlefield and Complex Traumatic Wound Infections in Austere or Contested Environments; Prevention and Treatment of Emerging Infectious Diseases; Development of Novel Non-Addictive Analgesics; and Advanced Anesthesia and Procedural Pain Solutions. https://mtec-sc.org/solicitations/multitopic	TBD	TBD
		BONE MARROW FAILURE (3)		
11.	FY26 Bone Marrow Failure Research Program (DoD/CDMRP) HT942526BMFRPIDA HT942526BMFRPIIRA HT942526BMFRPRDA	The BMRFP supports innovative, high-impact bone marrow failure research. Three awards have been posted: Idea Development Award; Investigator-Initiated Research Award; and Resource Development Award. Applications must address one or more of the following focus areas unless otherwise noted: Develop durable resources for the bone marrow failure research community; Find effective BMF treatments and cures; and Understand the causes and progression of BMF diseases. https://cdmrp.health.mil/funding/bmfrp	Up to $1.25 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 8/5/26 Proposal: 11/4/26 (IDA/IIRA) Pre-Application: 10/7/26 Proposal: 11/4/26 (RDA)
		CANCER (7)		
12.	Forecast: NCI SBIR Innovative Concept Award Program – Fiscal Year 2027 (NIH/NCI) 75N91026R00109	NCI will solicit proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Topic 1: Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers. Topic 2: Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. https://sam.gov/workspace/contract/opp/aeb9ea152c644006bc1e3e6942e260d9/view	TBD	Estimated post date: 7/17/26 Estimated proposal date: late September 2026
13.	FY26 Kidney Cancer Research Program (DoD/CDMRP) HT942526KCRPAKCIECSA HT942526KCRPCA HT942526KCRPIDA	The KCRP supports innovative, high-impact research with clinical relevance that will accelerate progress to eliminate kidney cancer. Three awards have been posted: Academy of Kidney Cancer Investigators – Early-Career Scholar Award; Concept Award; and Idea Development Award. Applications must address one or more areas of emphasis. https://cdmrp.health.mil/funding/kcrp	Up to $1.2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 7/28/26 Proposal: 8/11/26 (CA) Pre-Application: 9/14/26 Proposal: 9/28/26 (AKCIECSA/IDA)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
14.	FY26 Rare Cancers Research Program (DoD/CDMRP) HT942526RCRPCA HT942526RCRPIDA HT942526RCRPRCDA	The RCRP supports innovative, high-impact research with clinical relevance that will improve outcomes for people with rare cancers. Three awards have been posted: Concept Award; Idea Development Award; and Resource and Community Development Award. Applications must address one or more of the appropriate focus areas. https://cdmrp.health.mil/funding/rcrp	Up to $1.12 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/19/26 Proposal: 11/18/26 (IDA/RCDA) Pre-Application: 9/16/26 Proposal: 9/30/26 (CA)
		CENTRAL NERVOUS SYSTEM (1)		
15.	Forecast: BRAIN Initiative: Development and Validation of Novel Tools and New Approaches for Neuroscience Research (NIH) RFA-MH-28-110	This NOFO will solicit applications for research to develop novel tools and approaches that enable the interrogation of cell-specific and circuit-specific processes in the central nervous system. This NOFO consolidates three current BRAIN Initiative tool development programs. Projects that focus on developing a broad range of new research tools to delineate anatomical and functional connections between cells and circuits, and to expand our knowledge of brain architecture and function are encouraged. https://www.grants.gov/search-results-detail/362947	Total funding of $12 million	Estimated post date: 2/10/27 Estimated proposal date: 6/7/27
		CLINICAL TRIALS (8)		
16.	NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) (NIH/NIAID) PAR-27-064	This NOFO encourages applications for implementation of investigator-initiated, milestone driven clinical trials that need enhanced oversight, and as applicable, include mechanistic studies. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. https://www.grants.gov/search-results-detail/359859	Dependent upon proposal, for up to 7 years	Multiple deadlines; NOFO open through 7/5/29
17.	Forecast: Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (NIH/NIAMS) PAR-27-109	The goal of the NIAMS clinical trial program is to support research leading to the prevention or reduction of symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal, or skin conditions or diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these conditions or diseases. https://www.grants.gov/search-results-detail/362752	Up to $600,000	Estimated post date: 9/1/26 Estimated proposal date: 3/4/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CLINICAL TRIALS		
18.	Forecast: Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) (NIH) PAR-27-125	This NOFO will solicit applications to develop and implement investigator-initiated multi-site clinical trials, including efficacy, effectiveness, pragmatic, and/or implementation research clinical trials. Applications that propose a large and/or complex clinical trial conducted at either a single site or at multiple locations but without physical clinical sites may also be eligible. The objective of the application is to present 1) the scientific rationale as well as a comprehensive scientific and operational plan for the trial, and 2) a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial. https://www.grants.gov/search-results-detail/363025	TBD	Estimated post date: 11/16/26 Estimated proposal date: 2/16/27
19.	Forecast: NIAMS Clinical Trial Implementation Cooperative Agreement (NIH/NIAMS) PAR-28-031	This NOFO will solicit cooperative agreement applications for implementation of investigator-initiated, single or multi-site, interventional clinical trials. Investigators who have completed all necessary preparation through other means may apply for a NIAMS Cooperative Agreement Clinical Trial. The first phase is designed to allow the investigators to prepare the final aspects needed to start the trial. Transition to the second phase to begin the trial is dependent upon completion of the phase 1 milestones proposed by the investigator and approved by NIAMS. https://www.grants.gov/search-results-detail/362753	Award floor of $250,000	Estimated post date: 11/2/26 Estimated proposal date: 7/2/27
20.	Forecast: Collaborative Network for Clinical Research on Immune Tolerance (NIH/NIAID) RFA-AI-28-005	The purpose of this program is to enhance understanding of the underlying mechanisms of the induction, maintenance, and loss of immune tolerance in humans; and to develop improved tolerogenic interventions for the prevention and treatment of immune system mediated diseases. The three major scientific goals include: 1) conduct clinical trials to determine the safety and efficacy of promising tolerogenic strategies in liver, kidney and pancreatic islet transplantation; allergic diseases and asthma; and autoimmune diseases; 2) investigate the basic mechanisms of immune tolerance in these diseases as an integral part of clinical trials; and 3) develop, refine and validate immune assays to monitor the induction, maintenance, and loss of tolerance in these disorders. https://www.grants.gov/search-results-detail/362946	Total funding of $21.986 million	Estimated post date: 10/16/26 Estimated proposal date: 1/29/27
21.	Forecast: Clinical Data, Safety and Statistical Centers (CDSSC) (NIH/NIAID) RFA-AI-28-006	The overall objective of this program is to provide coordination and oversight for multiple activities in service to clinical research and mechanistic studies supported by NIAID. This program will provide a broad range of support critical for the design, development, implementation, and analysis of clinical research carried out by multiple division-supported programs in three disease areas: asthma and allergy, autoimmune diseases and transplantation. https://www.grants.gov/search-results-detail/362957	Total funding of $27.094 million	Estimated post date: 2/1/27 Estimated proposal date: 6/1/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CLINICAL TRIALS		
22.	Forecast: Clinical Trials in Organ Transplantation in Children and Adults (NIH/NIAID) RFA-AI-28-008	The goal of the CTOT-CA is to improve the outcome of organ transplantation through clinical trials with mechanistic studies. The CTOT-CA will support multicenter clinical trials, with associated studies of immune mechanisms, in heart, lung, kidney, liver, and intestinal transplantation. The program will also support clinical trials of non-hematopoietic cellular transplantation as replacement therapies; vascularized composite tissue transplantation; and transplantation of bone marrow or mesenchymal stem cells, or of immunologically active cells, as adjuncts to organ transplantation. https://www.grants.gov/search-results-detail/362955	Total funding of $11.28 million	Estimated post date: 6/17/27 Estimated proposal date: 9/30/27
23.	Forecast: Translational Centers Using Microphysiologic Systems for Infectious Diseases (NIH/NIAID) RFA-AI-28-012	NIAID seeks to advance its mission by supporting the development of human microphysiologic systems (MPS) for infectious disease research and the development of therapeutics or biological products. MPS are in vitro platforms composed of cells or tissues maintained in a microenvironment designed to mimic the physiological aspects of in vivo tissue or organ function. The goal of this program is to accelerate the use of MPS for infectious diseases and product development, promoting adoption for use by developers of drugs and biological products and their regulatory acceptance. https://www.grants.gov/search-results-detail/362954	Total funding of $7 million	Estimated post date: 11/13/26 Estimated proposal date: 1/29/27
		COGNITIVE AND BRAIN HEALTH (2)		
24.	Brain Repair of Any Injured Neural Structure (BRAINS) (ARPA-H) ARPA-H-SOL-26-148	BRAINS goal is to show it is possible to reverse damage and disease in any part of the brain. BRAINS ET will target brain regions. These areas control movement, balance, mood, autonomic body functions, memory formation, and other critical functions. The BRAINS ET approach will address a wide range of disabilities caused by many forms of brain damage, including aging, congenital diseases, strokes, injuries, tumors, and infections. Using natural brain development as a guide, BRAINS is focused on two technical areas, both essential for later steps in repairing damaged brain tissue with working tissue: Technical area 1: teams will design developmental mimicking or tissue engineering methods capable of generating precursor tissue for a part of the brain other than neocortex; Technical area 2: teams will provide proof-of-concept for surgical engraftment into adult brains of non-human fetal precursor tissues for their selected brain area. BRAINS ET will have two intake groups. Each group's work will last 18 months from kickoff to completion and will include two 9-month phases. https://sam.gov/workspace/contract/opp/91d0fa2d1867497592b88036cc3e3901/view	Dependent upon proposal and award mechanism	Intake Group 1: Solution Summary: 7/9/26 Proposal: 8/6/26 Intake Group 2: Solution Summary: 1/7/27 Proposal: 2/6/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
25.	Alzheimer's Disease Research Request for Proposals (BrightFocus)	The goal of the BrightFocus Foundation research grants program is to support innovative research promoting advances in the etiology, prevention, and treatments of Alzheimer's disease. The Foundation is interested in supporting high risk studies that illuminate areas for which there currently is little understanding. The Standard Award Program is divided into two tracks, the early career and independent investigator, each designed to support innovative research in ADRD. https://www.brightfocus.org/about/for-scientists/apply-for-a-research-grant/alzheimers-disease-research-request-for-proposals/	$100,000 per year, for up to 3 years	Proposal: 9/1/26
		COMBAT CASUALTY CARE (1)		
26.	Autonomous Closed Loop Control Mechanical Ventilation (ACLCMV) (MTEC) MTEC-26-02-Ventilator	This project seeks to develop an Autonomous Closed-Loop Control Mechanical Ventilator. This device will use advanced algorithms to automatically adjust ventilation settings for closed loop Positive End Expiratory Pressure (PEEP) based on the patient's physiological responses, minimizing the need for manual intervention. The goal is to create a lightweight, durable, and power-efficient ventilator that enhances patient safety and frees up medical personnel for other critical tasks during aeromedical evacuation and prolonged field care scenarios. https://mtec-sc.org/solicitations/ventilator-rpp	Up to $1.9 million, for up to 1 year	Proposal: 7/15/26
		COMBAT READINESS MEDICAL RESEARCH (1)		
27.	FY26 Combat Readiness-Medical Research Program (DoD/CDMRP) HT942526CRRPTRA	The CCRP supports innovative, high-impact research with clinical relevance that will lead to increased survivability and readiness of the Warfighter. One award has been posted: Translational Research Award. Applications submitted to the FY26 CRRP must address one or more of the following focus areas: Battlefield diagnostics, triage, and decision aid tools; Treatments; and Battlefield readiness. https://cdmrp.health.mil/funding/crrp	Up to $2.45 million, for to 3 years	Pre-Application: 8/17/26 Proposal: 11/18/26
		DENTAL AND CRANIOFACIAL RESEARCH (1)		
28.	NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) (NIH/NIDCR) PAR-27-058	This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected previously. https://www.grants.gov/search-results-detail/359946	Up to $500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 7/5/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DIAGNOSTICS (1)		
29.	PRimer and prObe Manufacturing PlaTform (PROMPT) (MTEC) MTEC-26-03-PROMPT	The primary objective is to develop, integrate, and demonstrate a fully automated, man-portable, and ruggedized prototype platform for the on-demand, expeditionary manufacturing of clinical-quality nucleic acid primers and probes. This system must be designed for operation in far forward or austere environments by non-specialist personnel. The capability will specifically address critical technology gaps by replacing traditional hazardous synthesis chemistry with a field-stable alternative and, most critically, integrating novel, on-board capabilities for both the automated purification and quality control validation of the resulting reagents. The successful outcome will be a self-contained system capable of producing sequence-verified, high-purity oligonucleotides from a digital sequence file within hours, thereby enabling a rapid, decentralized diagnostic response to novel biothreats without reliance on traditional laboratory infrastructure or cold chain logistics. https://mtec-sc.org/solicitations/prompt-rpp	Dependent upon proposal, for up to 2 years	Proposal: 7/24/26
		DIGESTIVE DISEASES (1)		
30.	Silvio O. Conte Digestive Diseases Research Core Centers (NIH/NIDDK) RFA-DK-27-119	The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. https://www.grants.gov/search-results-detail/360436	Up to $750,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 2/10/27
		DIGITAL HEALTH (1)		
31.	Forecast: Digital Health Technology and Reciprocal Innovation to Improve Clinical and Public Health Outcomes (NIH/FIC) PAR-28-039	This initiative will support research on the development, validation, feasibility, and effectiveness of innovative digital health interventions or tools (including mobile health) specifically suited for underserved settings in the U.S. and globally. Research should utilize new or emerging technologies, platforms, systems, and/or analytics to address high priority health problems, expand the evidence base for the use of digital health technology to improve clinical and public health outcomes, and strengthen research collaborations between U.S. and low- and middle-income country (LMIC) researchers. Applications must include reciprocal innovation methodologies – bidirectional and iterative exchange of ideas, resources, and innovation approaches to address shared health challenges in the U.S. and a LMIC. https://www.grants.gov/search-results-detail/363049	TBD	Estimated post date: 12/1/26 Estimated proposal date: 2/11/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DUCHENNE MUSCULAR DYSTROPHY (2)		
32.	FY26 Duchenne Muscular Dystrophy Research Program (DoD/CDMRP) HT942526DMDRPIDA HT942526DMDRPCTRA	The DMDRP supports innovative, high-impact research with clinical relevance that will preserve and improve the function and quality of life across the lifespan of all individuals with Duchenne muscular dystrophy. Two awards have been posted: Idea Development Award and Clinical Translation Research Award. Applications must address one or more of the focus areas appropriate to their proposed work. https://cdmrp.health.mil/pubs/press/2026/dmdrppreann https://cdmrp.health.mil/funding/dmdrp	Up to $1.9 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 9/4/26 Proposal: 9/18/26
		ENDOCRINE & METABOLIC DISEASE (4)		
33.	Forecast: NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional) (NIH/NIDDK) RFA-DK-28-112	This NOFO will invite applications for NIDDK Disease Research and Translational Core Centers. These Core Centers are part of an integrated program of biomedical and translational research supporting our cystic fibrosis, diabetes, nutrition, obesity, liver and digestive diseases research. They enhance multidisciplinary collaboration, rigor, reproducibility, replication and research cost efficiencies at institutions that already have a large established research base in one of the above focused areas within NIDDK's mission. https://www.grants.gov/search-results-detail/363052	Total funding of $28 million	Estimated post date: 4/30/27 Estimated proposal date: 6/1/27
34.	Forecast: NIDDK Multi-Purpose Resource-Related, Multi-Component Research Services Centers Cooperative Agreement (U2C - Clinical Trial Optional) (NIH/NIDDK) RFA-DK-28-114	To help increase rigor, reproducibility and cost efficiencies, U2C centers offer highly specialized cores that provide a range of topic focused services including but not limited to hands-on technical services, consulting, research/data coordination, or other research support services provided by nationally recognized experts. In contrast to other types of Core Centers, the U2C services should be largely provided to clients located at another institution where the needed service or expertise is not available. Provided services enable high impact research within NIDDK's research mission including but not limited to integrative physiology, metabolic phenotyping, nutrition, community engagement, communications, and/or data and research coordination. https://www.grants.gov/search-results-detail/363037	Total funding of $9 million	Estimated post date: 11/28/26 Estimated proposal date: 1/28/27
35.	Forecast: KUH P30 Resource Core Center and U24 Center Coordinating Hub (P30/U24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-28-312 RFA-DK-28-313	These NOFOs will request applications for Resource Core Centers and Center Coordinating Hubs within the mission of NIDDK/Kidney, Urology, and Hematology (KUH) Diseases. The Core Centers and Coordinating Hubs will work collaboratively to develop and share unique research resources (e.g., data, reagents, models, tools, services, expertise) with the broader community. https://www.grants.gov/search-results-detail/363036 (P30) https://www.grants.gov/search-results-detail/363039 (U24)	TBD	Estimated post date: 12/1/26 Estimated proposal date: 1/30/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENVIRONMENTAL HEALTH (1)		
36.	Forecast: Health and Extreme Weather Solutions-Focused Research Hubs and Research Coordination and Data Center (U54 - Clinical Trial Optional/U2C - Clinical Trial Not Allowed) (NIH/NIEHS) RFA-ES-28-002	These NOFOs will solicit applications that propose translational research hubs and research coordination and data support for the HEW initiative. The hubs will focus on research, capacity building, and community/public health translation for regionally relevant topics related to the health impacts of extreme weather and cumulative exposures. https://www.grants.gov/search-results-detail/362978 (U54) https://www.grants.gov/search-results-detail/362979 (U2C)	Up to $2 million (U54) Up to $3 million (U2C)	Estimated post date: 11/27/26 Estimated proposal date: 1/29/27
		GENOMICS (5)		
37.	Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) (NIH) PAR-27-071	The NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program supported genomic data generating centers. Applicants are encouraged to propose sequencing of existing pediatric cancer or congenital anomaly cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of congenital anomalies, to study the molecular basis of the associations between congenital anomalies and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. https://www.grants.gov/search-results-detail/361164	Research support only (X01)	Proposal: 1/11/27
38.	Forecast: Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed) (NIH/NHGRI) PAR-27-119	The Center for Inherited Disease Research (CIDR) carries out high-throughput genotyping and sequencing and supports statistical genetics services designed to 1) aid identification of genes or genetic modifications that contribute to human health and disease or 2) enhance the classification and characterization of well-phenotyped specimens by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, services, and statistical genetic support. https://www.grants.gov/search-results-detail/362723	Research support only (X01)	Estimated post date: 8/10/26 Estimated proposal date: 9/3/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS		
39.	GREGoRi Data Coordination and Outreach Center, Technology Integration Center, and Innovation Projects (U01, Clinical Trials Not Allowed/Optional) (NIH/NHGRI) RFA-HG-27-011 RFA-HG-27-012 RFA-HG-27-013	The Genomics Research to Elucidate the Genetics of Rare Diseases: innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying rare genetic disorders. The Data Coordination and Outreach Center will act as the central point of coordination for the GREGoRi Research Program, and will be responsible for ensuring that the protocols, data, metadata, computational tools and other resources developed as part of GREGoRi are made available to the broader research community. The Technology Integration Center will enable the development of standards and best practices for applying new and emerging molecular methods in rare disease diagnosis. Innovation Projects are intended to stimulate the development and testing of highly innovative experimental or computational approaches for rare disease diagnosis, that have the potential to make transformative improvements to the current state of the art. https://www.grants.gov/search-results-detail/359279 https://www.grants.gov/search-results-detail/359280 https://www.grants.gov/search-results-detail/359644	Up to $2.25 million Dependent upon proposal and award mechanism	Proposal: 10/30/26
		HEALTH IT & DATA (1)		
40.	Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional) (NIH/NIDA) PAS-27-028	This NOFO aims to facilitate the entry of investigators into multiple high-priority areas of substance use research, including comorbidity with HIV. The Science Track Award for Research Transition (START) Program aims to provide investigators with the opportunity to gather preliminary data that will assist them in securing future research grants and advancing their scientific careers. https://www.grants.gov/search-results-detail/360553	Up to $100,000 per year, for up to 2 years	Multiple deadlines; NOFO open through 3/16/29
		HIV/AIDS (2)		
41.	Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional) (NIH/NIA) PAR-27-026	This NOFO supports innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder. https://www.grants.gov/search-results-detail/358991	Up to $700,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 9/28/28

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
42.	Forecast: AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) (NIH/NIMH) PAR-28-033	This NOFO will seek research applications to support the NIMH HIV/AIDS Research Centers (ARC) program, including Developmental Centers (D-ARCs) and full AIDS Research Centers (ARCs). These Research Centers aim to capitalize on the coordinated infrastructure to advance high-impact, interdisciplinary HIV/AIDS research. The ARC program supports innovative research across basic, neuro-HIV, behavioral and social, clinical, translational, implementation science, and data science domains. Centers are expected to foster scientific collaboration, accelerate innovation, and strengthen dissemination of research advances to implementing agencies, affected communities, and other stakeholders. https://www.grants.gov/search-results-detail/362945	Total funding of $1.5 million	Estimated post date: 2/25/27 Estimated proposal date: 5/25/27
		IMMUNOLOGY & INFECTIOUS DISEASE (14)		
43.	Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB) (NIH/NIAID) BAA-75N93026R00008	The objective of this solicitation is to accelerate TB vaccine development by supporting research that characterizes both tissue-specific and systemic protective immune responses that prevent or contain Mycobacterium tuberculosis (Mtb) infection, and the advancement of tools and resources that facilitate TB vaccine development. This program will continue to support the comprehensive understanding of protective immunity to Mtb and the impact of Human Immunodeficiency Virus/Simian Immunodeficiency Virus (HIV/SIV) infection on responses to Mtb and TB vaccines. This solicitation also requires the use of human samples and/or clinical studies, at least one animal model, and computational data integration and modeling for cross-comparative analyses of the human and animal studies. In addition, investigators may consider using organoids or other ex-vivo systems to assess human immunity to Mtb or TB vaccines. https://sam.gov/workspace/contract/opp/c9c1ca45da4d49db89cf842d18f8920f/view	Dependent upon proposal and award mechanism	Proposal: 9/1/26
44.	Enhancing global laboratory systems to safely manage biological risks, deploy diagnostics and sequence pathogens to strengthen health protection worldwide (CDC/GHC) CDC-RFA-JG-26-0058	Activities under this NOFO will focus on protecting and improving public health globally by: 1) strengthening public health laboratory systems; 2) improving public health laboratory workforce; 3) improving bio risk management; 4) reinforcing emergency laboratory preparedness in alignment with 7-1-7 outbreak response paradigm; 5) enhancing laboratory quality management systems and; 6) enhancing diagnostic capacity via rapid tests for low resource settings and genomic sequencing for pathogens of pandemic potential. https://www.grants.gov/search-results-detail/360343	Total funding of $25 million	Proposal: 7/13/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
45.	Enhancing Global Health Security: Strengthening public health surveillance systems for disease detection and preparedness globally (CDC/GHC) CDC-RFA-JG-26-0113	This NOFO is intended to support global health security partners to develop or continue the implementation of surveillance activities that focus on protecting and improving public health globally through strategic planning, policy, strengthening surveillance capacities and systems through partnerships. These surveillance systems should build and improve regional and country capacities to detect, respond, control, and prevent infectious diseases and emerging threats; strengthen border health security; and mitigate public health events of international concern (PHEICs) or other global health issues. https://www.grants.gov/search-results-detail/360617	Total funding of $15 million	Proposal: 7/15/26
46.	Forecast: Translational Transplantation Tolerance Cooperative Study Group (NIH/NIAID) RFA-AI-28-010	The overarching goal of this program is to facilitate clinical translation of safe and effective transplant tolerance regimens that achieve long-term graft survival without the need for life-long administration of immunosuppressive drugs. This program will enable establishment of a multi-center, cooperative program dedicated to developing, optimizing, and evaluating approaches to induce and maintain immune tolerance to allogeneic transplants, which will be tested in translationally relevant models. https://www.grants.gov/search-results-detail/362958	Total funding of $10.46 million	Estimated post date: 1/21/27 Estimated proposal date: 5/21/27
47.	Forecast: Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases (NIH/NIAID) RFA-AI-28-014	NIAID seeks to advance its mission by supporting multidisciplinary, consortium-based research using precision systems biology approaches to uncover links among chronic illnesses, infectious diseases and microbiomes. There is an urgent scientific and clinical need to understand the pathways by which infections lead to chronic lifelong health issues or alternatively, how long-term illnesses might predispose or exacerbate acute infections. The objective is to harness cutting-edge technologies along with longitudinal patient cohorts and biobank data for comprehensive analysis of genetic, environmental, and lifestyle factors leading to advances in prevention and treatment strategies for both chronic and infectious diseases. The cutting-edge technologies may include multi-omics, computational modeling, artificial intelligence, organoid-based validation systems, and integration of real-world data, alongside improved access to digital health records and advanced clinical informatics tools. The goal is to generate meaningful insights into disease progression and host-pathogen interactions. https://www.grants.gov/search-results-detail/362952	Total funding of $17 million	Estimated post date: 11/6/26 Estimated proposal date: 1/22/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
48.	Forecast: Improved Drug Susceptibility Testing (DST) for Mycobacteria (NIH/NIAID) RFA-AI-28-018	NIAID seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. https://www.grants.gov/search-results-detail/362948	Total funding of $3 million	Estimated post date: 3/12/27 Estimated proposal date: 5/28/27
49.	RFI: Advanced Clinical Development and Licensure of an Adjuvanted Egg-based Influenza Vaccine (BARDA/RRPV) RFI: AdjEgg	This RFI seeks to understand the availability of egg-based pandemic influenza vaccines based on licensed seasonal influenza vaccines and licensed adjuvants to ensure the long-term commercially sustained capabilities. https://www.rrpv.org/solicitation/request-for-information-advanced-clinical-development-and-licensure-of-an-adjuvanted-egg-based-influenza-vaccine/	N/A	Response: 7/10/26
50.	RFI: High Performance Antigen Diagnostics (BARDA/RRPV) RFI: HiPe	The objective of this RFI is to better understand the research, development, and product landscape of current and next-generation high-performance immunoassay technologies suitable for antigen testing in near-patient settings. This RFI seeks to understand both currently available systems and emerging technologies, including integrated platforms and enabling components, that can bring ultra-sensitive performance into smaller, faster, more deployable, and ideally multiplexed platforms or formats. https://www.rrpv.org/solicitation/rfi-high-performance-antigen-diagnostics/	N/A	Response: 7/17/26
51.	Innovations in Decentralized Pan-Orthoebolavirus Diagnostics (Gates Foundation)	This Grand Challenge seeks specific, field-ready innovations in pan-Orthoebolavirus diagnostics that address the concrete gaps exposed by the 2026 outbreak and prepare the global community for the next one. The Challenge aims to: Generate scientific foundations; Accelerate development of field-deployable diagnostic products; Build population-level early-warning capacity; and Strengthen quality assurance and implementation infrastructure to ensure that decentralized VHF testing is reliable, trustworthy, and sustained between outbreaks. Five opportunities are offered, each with its own funding level and duration. They are: 1) Biomarkers; 2) Specimen Innovations; 3) Diagnostic Products; 4) Surveillance and early warning; 5) Quality and Implementation. https://gcgh.grandchallenges.org/challenge/innovations-decentralized-pan-orthoebolavirus-diagnostics	Up to $800,000, for up to 3 years Dependent upon proposal and opportunity	Proposal: 7/31/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
52.	Hit-to-Lead Platform (HTLP) (GHIT Fund)	The Hit-to-Lead Platform (HTLP) leverages the medicinal chemistry expertise in Japan and facilitates access to relevant and diverse compounds to address the unmet needs of the following diseases: Malaria; Tuberculosis; Chagas Disease; Schistosomiasis; and Viral Infectious Diseases with Pandemic Potential. HTLP focuses on the aspect of the drug discovery and development process that advances hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to GHIT's Product Development Platform that begins with the lead-optimization step. https://www.ghitfund.org/applyforfunding/htlp/en	Dependent upon proposal and award mechanism	Letter of intent: 8/14/26 Proposal: 9/18/26
53.	Product Development Platform (GHIT Fund)	The GHIT Fund announces the RFP for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects may focus on R&D activities in the development stages as illustrated in https://www.ghitfund.org/applyforfunding/opportunities, including: Lead optimization; Preclinical Development; Clinical Development; Parallel or concurrent development of multiple interventions; and Activities to support licensure and WHO prequalification. Applicants must include at least one Japanese organization and one non-Japanese organization. https://www.ghitfund.org/applyforfunding/pdp/en	Up to 5,000,000 JPY, for up to 2 years Cost sharing required	Letter of intent: 7/10/26 Proposal: 8/7/26
54.	Target Research Platform (GHIT Fund)	The Target Research Platform (TRP) is intended to support the crucial, earlier phase of R&D discovery of new approaches, concepts, constructs and solutions to fight neglected infectious diseases. Three awards are included: Standard TRP Award; Strategic Innovation and Market Assessment Award (SIMA Award); and Pandemic Preparedness and Response Award (PPR Award). https://www.ghitfund.org/applyforfunding/trp/en	Up to 100,000,000 JPY, for up to 2 years Dependent upon award mechanism	Letter of intent: 7/10/26 Proposal: 8/7/26
		JOINT WARFIGHTER MEDICAL RESEARCH PROGRAM (1)		
55.	FY26 Joint Warfighter Medical Research Program (DoD/CDMRP) HT942526JWMRPMMRDA	The JWMRP aims to augment and accelerate progress toward critical medical capability gaps and requirements through the continuation of research and development initiatives that were previously supported that are close to achieving their objectives and yielding a benefit to military medicine. One award has been posted: Military Medical Research and Development Award. All applications must address one or more of the focus areas. https://cdmrp.health.mil/funding/jwmrp	Up to $3 million, for up to 3 years	Pre-Application: 8/18/26 Proposal: 11/16/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL MANUFACTURING (2)		
56.	RFI: Repurposing Equipment for Drug Delivery (BARDA/RRPV/BioMaP) RFI: REDD	Through this RFI, BARDA seeks input from industry, academia, and other stakeholders regarding transformative approaches that will repurpose specialized equipment that was originally customized to manufacture an emergency autoinjector platform, featuring a novel glass-free, collapsible, primary drug container (PDC), made from high barrier films. This equipment includes specific items that involve handling, cleaning, forming the Polyvinyl chloride (PVC) film in specific conformations, placement into a pre-assembly configuration, fill, and finishing the sealing of the primary drug cartridge. https://www.rrpv.org/solicitation/request-for-information-repurposing-equipment-for-drug-delivery/	N/A	Response: 7/23/26
57.	Digital Stockpile & Manufacturing Response Network (DS-MRN) (NASA/ASPR)	This two-phase federal innovation challenge is focused on practical, scalable solutions for distributed supply chain disruption response, secure digital coordination, interoperability, and emergency preparedness. Innovators have the rare opportunity to develop complex systems concepts from ideation to live validation. Multiprong solutions will address the need for a secure digital infrastructure of medical product designs and a network of domestic industry manufacturers ready to produce and deliver at-risk medical goods during supply chain disruptions and crises. https://www.expeditionhacks.com/pre-launch/digital-stockpile-challenge	Total prizes of $2.04 million	TBD
		MICROPLASTICS RESEARCH (1)		
58.	Forecast: Microplastics Research and Resource Coordination Center (U24 - Clinical Trial Not Allowed) (NIH/NIEHS) RFA-ES-27-003	The goal of the Micro/Nanoplastics (M/NPs) Research and Resource Coordination Center initiative is to establish a robust center that will coordinate and advance multidisciplinary efforts among biomedical and material science researchers to gain a comprehensive understanding of the health effects of M/NPs. This coordination center will accelerate the development and dissemination of sampling and analytical standardization, data harmonization, and distribution of experimental standards across the field of M/NPs research. The established coordination center will provide leadership and guidance that fosters collaboration across the M/NPs research community and promotes best practices that enhance the reliability and validity of research findings in this area. https://www.grants.gov/search-results-detail/362996	Total funding of $2 million	Estimated post date: 10/1/26 Estimated proposal date: 12/1/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NEUROFIBROMATOSIS (5)		
59.	FY26 Neurofibromatosis Research Program (DoD/CDMRP) HT942526NFRPNFRALA HT942526NFRPNFRASA HT942526NFRPEHDA HT942526NFRPIIRA HT942526NFRPSIA	The NFRP supports innovative, high-impact research with clinical relevance that will improve the understanding, diagnosis and treatment Neurofibromatosis and schwannomatosis to enhance the quality of life for persons with these disorders. Five awards have been posted: Exploration-Hypothesis Development Award; Investigator-Initiated Research Award; Neurofibromatosis Research Academy – Leadership Award; Neurofibromatosis Research Academy – Scholar Award; and Synergistic Idea Award. Applications must address one or more areas of emphasis. https://cdmrp.health.mil/funding/nfrp	Up to $2.4 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/31/26 Proposal: 9/14/26 (ALA) Pre-Application: 9/8/26 Proposal: 9/22/26 (ASA/EHDA/ IIRA/SIA)
		NIH COMMON FUND (4)		
60.	NIH Director's Early Independence Awards (DP5 Clinical Trial Optional) (NIH Common Fund) RFA-RM-26-004	The NIH Director's Early Independence Award supports rigorous and promising investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. Applications in any area within the biomedical sciences are welcome. https://www.grants.gov/search-results-detail/360988	Up to $350,000	Proposal: 9/10/26
61.	NIH Director's Pioneer Award (DP1 Clinical Trial Optional) (NIH Common Fund) RFA-RM-27-001	The NIH Director's Pioneer Award supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere. Applications in all topics relevant to the broad mission of NIH are welcome. Research may involve basic, translational, or clinical research. https://www.grants.gov/search-results-detail/360986	$700,000 per year, for up to 5 years	Proposal: 9/9/26
62.	NIH Director's New Innovator Award (DP2 Clinical Trial Optional) (NIH Common Fund) RFA-RM-27-002	The NIH Director's New Innovator Award supports early-stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications in any area within the biomedical sciences are welcome; topics may involve basic, translational, or clinical research. https://www.grants.gov/search-results-detail/360987	Up to $475,000 per year, for 5 years	Proposal: 8/17/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NIH COMMON FUND		
63.	NIH Director's Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional) (NIH Common Fund) RFA-RM-27-003	The NIH Director's Transformative Research Award supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications in any area within the biomedical sciences are welcome; topics may involve basic, translational, or clinical research. https://www.grants.gov/search-results-detail/361084	Dependent upon proposal, for up to 5 years	Proposal: 9/3/26
		NUTRITION AND OBESITY RESEARCH (3)		
64.	Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional) (NIH/NIDDK) RFA-DK-27-120	This NOFO invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The NORC program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and a Scientific Catalyst program. https://www.grants.gov/search-results-detail/360544	Up to $750,000 per year, for 5 years	Proposal: 10/20/26
65.	Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers and Research Coordinating Center (U01 Clinical Trial Required/U24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-27-121 (U01) RFA-DK-27-136 (U24)	These NOFOs invite applications to participate in a consortium to test AOM treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being, and quality of life and be feasible to implement in clinical care settings. https://www.grants.gov/search-results-detail/360387 (U01) https://www.grants.gov/search-results-detail/360441 (U24)	Up to $1 million per year, for up to 5 years	Proposal: 10/9/26
		ORTHOPAEDIC RESEARCH (1)		
66.	FY26 Orthopaedic Research Program (ORP) (DoD/CDMRP) HT942526ORPARA HT942526ORPCRA	The ORP supports innovative, high-impact research with clinical relevance that will advance treatment and rehabilitation from orthopaedic injuries sustained during combat and service-related activities to optimize function and maximize return to duty. Two awards have been posted: Applied Award and Clinical Research Award. The Clinical Research Award has two funding levels: Funding Level 1: Supports Clinical Research and Funding Level 2: Supports Clinical Trials. Applications must address one or more focus areas, including: Battlefield Fracture-Related Infection; Osteointegration Outcomes; and Military Women's Health. https://cdmrp.health.mil/funding/prorp	Up to $3.2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/19/26 Proposal: 11/18/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PARKINSON'S DISEASE (2)		
67.	FY26 Parkinson's Research Program (DoD/CDMRP) HT942526PRPEIRA HT942526PRPIIRA	The PRP supports innovative, high-impact research with clinical relevance that will decrease risk, slow progression, or ease symptoms of Parkinson's disease. Two awards have been posted: Early Investigator Research Award and Investigator-Initiated Research Award. All applications must address one or more focus areas. https://cdmrp.health.mil/funding/prp	Up to $2 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 10/23/26 Proposal: 11/6/26
		RECONSTRUCTIVE TRANSPLANT (1)		
68.	FY26 Reconstructive Transplant Research Program (RTRP) (DoD/CDMRP) HT942526RTRPCA	The RTRP aims to advance science and clinical practice of vascularized composite allotransplantation, or VCA. One award, the Concept Award, has been posted. All applications must address one or more of the focus areas. https://cdmrp.health.mil/funding/rtrp	Up to $200,000, for up to 18 months	Pre-Application: 9/2/26 Proposal: 9/16/26
		REGENERATIVE MEDICINE (1)		
69.	Technology InteGrator and AcceleratoR (TIGAR) Exploratory Topic (ARPA-H) ARPA-H-SOL-26-144	TIGAR Exploratory Topic will forge entirely new paths to stabilizing regenerative tissues and organs by seeding the development of enabling technologies that can unlock temperature-flexible storage in increasingly larger and more complex biological systems. Solutions may involve any combination of new materials, artificial intelligence/machine learning, high-throughput screening methods, biological interventions, devices, processing methods, analytical technology, and packaging approaches that can overcome current roadblocks and yield a leap in the ability to store and distribute complex biologics, without introducing high cost or complexity. https://sam.gov/workspace/contract/opp/56326303c136466388706de839ffc00e/view https://sam.gov/workspace/contract/opp/6999269ee62f4695b39c83f79d6a4ff0/view	Dependent on proposal and award mechanism	Intake group 2: Solution Video: 12/8/26 Proposal: 2/5/27
		SKIN DISEASE (1)		
70.	Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) (NIH/NIAMS) RFA-AI-27-004	This NOFO aims to solicit applications for the Atopic Dermatitis Research Network (ADRN) program. The ADRN program will support Centers that integrate clinical and translational research to improve our understanding and management of atopic dermatitis with emphasis on chronic skin inflammation and the defense mechanisms of the skin. https://www.grants.gov/search-results-detail/360874	Up to $750,000 per year, for 5 years	Proposal: 9/24/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SLEEP HEALTH (1)		
71.	Restorative and health-Enhancing Sleep Time (REST) (ARPA-H) ARPA-H-SOL-26-159	ARPA-H seeks proposals for the Restorative & health-Enhancing Sleep Time (REST) program, a bold effort to transform how poor sleep is measured and treated by enabling objective, home-based, closed-loop technologies that detect health-relevant sleep microstructures and respond to them in real time. If successful, REST will establish the technical foundation for a new generation of sleep health technologies that are objective, personalized, and capable of improving long-term health outcomes at scale. https://solutions.arpa-h.gov/events https://sam.gov/workspace/contract/opp/6f8c0f1a75ed44b691b7c2a4e6ce0e47/view	Dependent on proposal and award mechanism	Proposers' Day: 7/13/26 Solution Summary: 8/12/26 Proposal: Fall 2026
		SMALL BUSINESS DEVELOPMENT (2)		
72.	Advanced Research Projects Agency for Health (ARPA-H) Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Program (ARPA-H) 7599226SN106	ARPA-H is soliciting proposals from SBCs that possess the R&D expertise to conduct innovative research that will contribute toward ARPA-H mission needs, SBIR, STTR program objectives. The following research topics are currently included in this solicitation: ARPA-H 01 - Development of an annual test to inform women about their future fertility ARPA-H 02 - Versatile Bioadhesives ARPA-H 03 - Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT) ARPA-H 04 - Breaking Ground: The First Curative, Non-Invasive, Long-Lasting Therapy for Endometriosis ARPA-H 05 - ARPA-H Lineage Topic ARPA-H 06 - Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease ARPA-H 07 - Virtual Human Brain for the Development of Neurosurgical Robotics. https://solutions.arpa-h.gov/events https://sam.gov/workspace/contract/opp/34fa75da1d484987bd6dbc882deab889/view	Up to $600,000 (Phase I) Up to $3.5 million (Phase II) Funding and duration is determined by the topic area.	Solution Summary: 7/10/26 Proposal: Dependent upon topic
73.	DoW SBIR 2026 BAA Release 4 (DoD) DoD SBIR 2026 BAA	Topics include: UH-60M Patient Handling System; Neuromorphic Hardware; T3CP Patent Holiday SBIR Open Topic Call; and Domestic Production of Plant-based Carbon Fiber Precursors in Support of Hypersonic Applications. https://www.dodsbirsttr.mil/topics-app/	Up to $209,575, for up to 6 months (Phase I) Up to $1.397 million, for up to 2 years (D2P2)	Proposal: 8/19/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER (1)		
74.	Forecast: Solutions for Linkage to Care Implementation Challenges for People with Opioid Use Disorder (CDC/ERA) RFA-CE-27-017	This NOFO will solicit investigator-initiated research to develop, implement, and rigorously evaluate strategies to address and overcome barriers to implementing evidence-based linkage to care services in health care settings. Strategies should focus on individuals with OUD or who meet criteria consistent with an OUD and are at risk of an opioid overdose with or without involvement of other substances. Applicants are expected to have at least one partnership with a public health entity or bona fide agent to identify solutions to challenges in linkages to care. https://www.grants.gov/search-results-detail/363058	Up to $550,000	Estimated post date: 10/1/26 Estimated proposal date: 8/29/27
		THERAPEUTICS (2)		
75.	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development (NIH) PAR-28-043	The BPN-SM program supports drug discovery and development activities in investigators' own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development. https://www.grants.gov/search-results-detail/363095	TBD	Estimated post date: 11/15/26 Estimated proposal date: 6/16/27
76.	HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) (NIH) RFA-NS-27-007	This NOFO supports the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. https://www.grants.gov/search-results-detail/359161	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 2/20/29
		VISION RESEARCH (5)		
77.	Macular Degeneration Research Request for Proposals (BrightFocus)	The goal of the BrightFocus Foundation research grants program is to support innovative research promoting advances in the etiology, prevention, and treatments of macular degeneration. Three tracks are offered: Postdoctoral Fellowship Program; New Investigator Grant Program; and Standard Award Program. These awards will support studies that have an impact on the causes and/or treatment of macular degeneration. https://www.brightfocus.org/about/for-scientists/apply-for-a-research-grant/macular-degeneration-research-request-for-proposals/	Up to $150,000 per year, for up to 3 years	Proposal: 7/30/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		VISION RESEARCH		
78.	National Glaucoma Research Request for Proposals (BrightFocus)	The goal of the BrightFocus Foundation research grants program is to support innovative research promoting advances in the etiology, prevention, and treatments of glaucoma. The Foundation is interested in supporting high risk studies that illuminate areas for which there currently is little understanding, helping to bring to light crucial knowledge. https://www.brightfocus.org/about/for-scientists/apply-for-a-research-grant/glaucoma-apply-for-grant/	Up to $150,000 per year, for 2 years	Proposal: 9/24/26
		WOMEN'S HEALTH (2)		
79.	NAVIGATE Reproductive Center of Excellence (Network for Assessment, Validation, Innovation, Guidance, Access, Treatment and Evaluation) (HHS/OASH) WH-AST-26-003	This notice solicits applications from organizations with demonstrated experience in the prevention, diagnosis, and treatment of reproductive health conditions, which may include polyendocrine metabolic ovarian syndrome (PMOS, formerly known as polycystic ovary syndrome or PCOS), endometriosis, uterine fibroids, infertility, pelvic inflammatory disease (PID), reproductive-age endocrine disorders, or recurrent miscarriage. Through this cooperative agreement, selected organizations will be recognized and elevated as a Center of Excellence, building on their existing expertise to strengthen the translation of evidence into practice, enhance and standardize root-cause care pathways, expand workforce training, and improve health outcomes for women. https://www.grants.gov/search-results-detail/362933	Up to $500,000 Cost sharing required	Proposal: 7/24/26
80.	Medical Forensic Access Initiative (HHS/OASH) WH-AST-26-004	This NOFO solicits applications for practical, data-driven, and scalable projects that support organizations in collecting, analyzing, and reporting information related to access to medical forensic examinations for women and girl survivors of sexual assault. Projects funded under this initiative should identify barriers, service gaps, workforce shortages, geographic gaps, wait times, and system-level challenges impacting women and girl survivor access to timely, forensic healthcare services. https://www.grants.gov/search-results-detail/362966	Up to $1 million, for up to 3 years	Proposal: 7/27/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
81.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
82.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
83.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/workspace/contract/opp/c79df057a7e44d2cb3072e4ce3307422/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
84.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
85.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
86.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadb41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
87.	Research Interests of the Air Force Office of Scientific Research FA9550-26-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological natural by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://grants.gov/search-results-detail/362681	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
88.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (10)		
89.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
90.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/e7c3faad3433434aaf41a5eb5ce11920/view	Dependent upon proposal	Proposals accepted on a rolling basis through 12/31/2060
91.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
92.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
93.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-c0bea38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
94.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available. https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
95.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
96.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
97.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
98.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/85b4747beec740979ac430ee987bda8c/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
99.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/workspace/contract/opp/8170c4735df64714adb2d1f8ce8671b1/view	Dependent upon proposal	Proposal: 9/25/28
100.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to $750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (3)		
101.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats, human-made or naturally occurring; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/opp/4f1cbdbab2a14330817746c9a7ec01bca/view	Dependent upon proposal and award mechanism	Proposal: 5/30/26
102.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/30/26
103.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3f0bedbf22c4e2daf5bb0a713f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
104.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
105.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
106.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8e0d71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
107.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to $1 million per year, for up to 5 years	White papers accepted through 9/2034

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
108.	FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003600	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature's mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/360678	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/26
		NATIONAL SCIENCE FOUNDATION (6)		
109.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs SBIR/STTR: Developing Deep Technologies that Advance U.S. Competitiveness and Security NSF 26-510	The NSF SBIR/STTR programs invest in start-ups and small businesses to turn high-risk, high-impact research into market-ready innovations. These programs aim to advance innovation by investing in the development of critical and emerging technologies that yield market-ready or commercializable outputs, all the while harnessing the full geography of American innovation and building a competition-ready workforce. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology/nsf26-510/solicitation	Up to $305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 7/27/26
110.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs : A Pilot Emphasis on Scientific Instrumentation NSF 26-511	The NSF SBIR/STTR and Fast-Track programs assist startups and small businesses in developing next-generation scientific instrumentation to support the S&E enterprise. These programs aim to spur innovation by investing in the development of critical and emerging technologies that advance basic science, innovation, and commercialization, thereby making entirely new fields of scientific discovery possible. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology-0/nsf26-511/solicitation	Up to $305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 7/27/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION		
111.	Biotechnology Opportunities PD-26-369Y PD 26-366Y PD 26-367Y PD 26-370Y	EBBS supports studies of mechanisms that drive the behavior of microbial populations and cells, and of therapeutic cells and tissues. Innovative TP research supports advances in artificial intelligence; manufacturing; biotechnology; microelectronics; energy generation, extraction, and utilization; nuclear energy; quantum science and engineering; and other national priorities. Research supported by the CPS program covers the full breadth of chemical and biochemical process innovation. EER supports research that transforms biotechnology and manufacturing to create domestic sources of energy; engineered chemical, biological, and/or geo-physical processes may be involved. https://www.nsf.gov/funding/opportunities/engineering-biological-biomedical-systems https://www.nsf.gov/funding/opportunities/transport-phenomena https://www.nsf.gov/funding/opportunities/chemical-process-systems https://www.nsf.gov/funding/opportunities/engineering-environmental-resiliency	Dependent upon proposal, for up to 5 years	Proposals accepted anytime
		NAVY (2)		
112.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/0efe2fde0926428f8ecc073f3fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/26
113.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/0c6f40ff4b65423c821921aa8b94a62e/view	Dependent upon proposal and award mechanism	White papers accepted through 9/30/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
114.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (7)		
115.	Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 3 2026	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-3-2026	Up to $1.5 million, for up to 3 years	System opens: 8/4/26 Letter of intent: 9/8/26 Proposal: 1/12/27
116.	Broad Pragmatic Studies Funding Announcement -- Cycle 3 2026	PCORI seeks to fund patient-centered CER comparing two or more alternatives, each of which has established efficacy and/or is in widespread use. PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2026 BPS PFA may select up to three of PCORI's Topic Themes; or "Other." Cycle 1 SAEs include: Addressing Obesity; Treatments and Strategies To Address Menopausal Symptoms; and Improving Care Delivery for Individuals With Intellectual and Developmental Disabilities (IDD). https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-3-2026	Up to $12 million, for up to 5 years Dependent upon award mechanism	System opens: 8/4/26 Letter of intent: 9/8/26 Proposal: 1/12/27
117.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 3 2026	PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in CER; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-3-2026	Up to $750,000, for up to 3 years	System opens: 8/4/26 Letter of intent: 9/8/26 Proposal: 1/12/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
118.	Engagement Award: Capacity Building -- Fall 2026 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-fall-2026-cycle	Up to $300,000, for up to 2 years	System opens: 8/4/26 Letter of intent: 10/1/26 Proposal: 1/11/27
119.	Engagement Award: Dissemination Initiative -- Fall 2026 Cycle	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-fall-2026-cycle	Up to $300,000, for up to 2 years	System opens: 8/4/26 Letter of intent: 10/1/26 Proposal: 1/11/27
120.	Engagement Award: Convening Support -- Fall 2026 Cycle	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-fall-2026-cycle	Up to $125,000, for up to 1 year	System opens: 8/4/26 Letter of intent: 10/1/26 Proposal: 1/11/27
121.	Engagement Award: Building Capacity for Small Organizations To Engage in Patient-Centered Comparative Clinical Effectiveness Research (CER) -- Fall 2026 Cycle	This PFA will fund projects that enable small organizations and their communities to build capacity and skills to engage in the patient-centered comparative clinical effectiveness research (CER) process. The projects will leverage each awardee organization's unique perspectives and experiences to build the knowledge, competencies and abilities of the organization and its community to be meaningful partners with researchers throughout all phases of the patient-centered CER process. https://www.pcori.org/funding-opportunities/announcement/engagement-award-building-capacity-small-organizations-engage-patient-centered-comparative-clinical-effectiveness-research-cer-fall-2026-cycle	Up to $300,000, for up to 2 years	System opens: 8/4/26 Letter of intent: 10/1/26 Proposal: 1/11/27

GBG Acronyms

Updated Monthly
July 8, 2026
https://www.g2gconsulting.com/gbg-reporting-service/

Terms
AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies
ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

NIH Institutes and Centers
CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:
https://us06web.zoom.us/j/84239203193?pwd=xs6MaVDJehY9wCNT48CIQPcWa6lzWh.1
Meeting ID: 842 3920 3193 Passcode: 841642

Back to Table of Contents